Home

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)

40.44
+1.13 (2.87%)
NASDAQ · Last Trade: Nov 26th, 1:05 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Millionfool.com
Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter
Via The Motley Fool · November 20, 2025
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offerfool.com
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way
Via The Motley Fool · November 20, 2025
Biotech Stock Gets Booted in Latest Fund Updatefool.com
Bain Capital sold its entire stake in Nuvalent stock during the third quarter.
Via The Motley Fool · November 19, 2025
7 Analysts Have This To Say About NewAmsterdam Pharmabenzinga.com
Via Benzinga · February 27, 2025
Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings)benzinga.com
Via Benzinga · January 24, 2025
Where NewAmsterdam Pharma Stands With Analystsbenzinga.com
Via Benzinga · December 30, 2024
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stockfool.com
Bain Capital completely exited its position in Disc Medicine stock during the third quarter
Via The Motley Fool · November 19, 2025
Why Bain Capital Is Selling Shares of This Biotech Stock Nowfool.com
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.
Via The Motley Fool · November 18, 2025
Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings)benzinga.com
Via Benzinga · October 20, 2025
Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analystsbenzinga.com
Via Benzinga · August 25, 2025
What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Cobenzinga.com
Via Benzinga · August 7, 2025
NewAmsterdam (NAMS) Q2 Revenue Jumps 49%fool.com
Via The Motley Fool · August 6, 2025
What Analysts Are Saying About NewAmsterdam Pharma Co Stockbenzinga.com
Via Benzinga · June 12, 2025
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapibbenzinga.com
NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.
Via Benzinga · June 9, 2025
Get insights into the top gainers and losers of Monday's pre-market session.chartmill.com
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · June 9, 2025
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · April 22, 2025
The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Expertsbenzinga.com
Via Benzinga · April 8, 2025
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?investors.com
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.
Via Investor's Business Daily · March 31, 2025
Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · February 26, 2025
Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · February 26, 2025
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · January 16, 2025
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?benzinga.com
These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN.
Via Benzinga · December 15, 2024
NewAmsterdam Pharma Stock Hits 90-Plus RS Ratinginvestors.com
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
Via Investor's Business Daily · December 11, 2024
Top 3 Health Care Stocks That May Collapse This Quarterbenzinga.com
Via Benzinga · December 11, 2024
NewAmsterdam Pharma Soars 41% On An Surprise Benefit From Cholesterol Druginvestors.com
The results bode well for an ongoing Phase 3 study examining cardiovascular outcomes.
Via Investor's Business Daily · December 10, 2024